In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin

Journal of Antimicrobial Chemotherapy

Volumn 39, Issue SUPPL. A, 1997, Pages 15-21

  Bouanchaud, D H ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DALFOPRISTIN; ERYTHROMYCIN; PENICILLIN G; QUINUPRISTIN; STREPTOGRAMIN DERIVATIVE;

ANTIBACTERIAL ACTIVITY; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; ENTEROCOCCUS FAECALIS; LEGIONELLA; MORAXELLA CATARRHALIS; MULTIDRUG RESISTANCE; MYCOPLASMA; NONHUMAN; POSTANTIBIOTIC EFFECT; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE;

EID: 0031010340     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/39.suppl_1.15     Document Type: Review

References (51)

1. Aumercier, M., Bouhallab, S., Capmau, M.-L. & Le Gofflc, F. (1992). RP 59500: a proposed mechanism for its bactericidal activity. Journal of Antimicrobial Chemotherapy 30, Suppl. A, 9-14.
2. Cocito, C., Di Giambattista, M., Nyssen, E. & Vannuffel, P. (1997). Inhibition of protein synthesis by streptogramins and related antibiotics. Journal of Antimicrobial Chemotherapy 39, Suppl. A, 7-13.
3. Barriere, J. C., Bouanchaud, D. H., Paris J. M., Polin, O., Harris, N. V. & Smith C. (1992). Antimicrobial activity against Staphylococcus aureus of semisynthetic injectable streptogramins: RP 59500 and related compounds. Journal of Antimicrobial Chemotherapy 30, Suppl. A, 1-8.
4. Bouanchaud, D. H. (1992). In-vitro and in-vivo synergic activity and fractional inhibitory concentration (FIC) of the components of a semisynthetic streptogramin, RP 59500. Journal of Antimicrobial Chemotherapy 30, Suppl. A, 95-100.
5. Neu, H. C., Chin, N. & Gu, J. (1992). The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, alone and in combination. Journal of Antimicrobial Chemotherapy 30, Suppl. A, 83-94.
6. Giambattisti, M., Chinali, G. & Cocito, C. (1989). The molecular basis of the inhibitory activities of type A and type B synergimycins and related antibiotics on ribosomes. Journal of Antimicrobial Chemotherapy 24, 485-507.
7. Pankuch, G. A., Jacobs, M. R. & Appelbaum, P. C. (1994). Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin and vancomycin by using time-kill methodology. Antimicrobial Agents and Chemotherapy 38, 2065-72.
8. Auckenthaler, R., Baquero, F., Braveny, I., Dornbusch, K., Kuval, J., Fleurette, J. et al. (1991). In vitro activity of RP 59500 against staphylococci: European multicenter study. In Program and Abstracts of the Thirty-First Interscience Conference of Antimicrobial Agents and Chemotherapy, Chicago, 1991. Abstract 900. American Society for Microbiology, Washington, DC.
9. Archer, G., Auger, P., Doern G., Ferraro M. J., Fuchs, P., Jorgensen, J. et al. (1993). RP 59500, a new streptogramin highly active against recent isolates of North American staphylococci. Diagnostic Microbiology and Infectious Diseases 16, 223-6.
10. Pass, R. J. (1991). In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci and enterococci. Antimicrobial Agents and Chemotherapy 35, 553-9.
11. Hoban, D. J., Weshnoweski, B., Palatnick, L., Zhanel, C. J. & Davidson, R. J. (1992). In-vitro activity of streptogramin RP 59500 against staphylococci, including bactericidal kinetic studies. Journal of Antimicrobial Chemotherapy 30, Suppl. A, 59-65.
12. Verbist, L. & Verhaegen, J. (1992). Comparative in-vitro activity of RP 59500. Journal of Antimicrobial Chemotherapy 30, Suppl. A, 39-44.
13. Andrews, J. M. & Wise, R. (1994). The in-vitro activity of a new semi-synthetic streptogramin compound, RP 59500, against staphylococci and respiratory pathogens. Journal of Antimicrobial Chemotherapy 33, 849-53.
14. Fremaux, A., Sissia, G., Cohen, R. & Geslin, P. (1992). Invitro activity of RP 59500, a new synthetic streptogramin, against Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 30, Suppl. A, 19-24.
15. Scriver, S. R., Lai, S. T. F., Chong, Y., Gonsales, A., Levi, M. & Low, D. E. (1994). In vitro activity of RP 59500 against Streptococcus pneumoniae, including isolates moderately susceptible and resistant to penicillin. In Program and Abstracts of the First International Conference on Macrolides, Azalides and Streptogramins, Venice, 1994.
16. Barry, A. L. & Fuchs, P. C. (1995). In vitro activities of a streptogramin (RP 59500), three macrolides, and an azalide against four respiratory tract pathogens. Antimicrobial Agents and Chemotherapy 39, 238-40.
17. Pankuch, G., Jacobs, M. & Appelbaum, P. (1996). Antipneumococcal activity of RP 59500 (an injectable streptogramin), erythromycin and sparfloxacin by MIC and rapid time-kill. In Pro- gram and Abstracts of the Third International Conference on Macrolides, Azalides and Streptogramins, Lisbon, 1995.
18. Reinert, R., Kresken, M., Lemperte, M. & Lutticken, R. (1996). In vitro antibacterial activity of RP 59500 (quinupristin/dalfopristin), a semisynthetic streptogramin combination, against Streptococcus pneumoniae. In Program and Abstracts of the Third International Conference on the Macrolides, Azalides and Streptogramins, Lisbon, 1996. Abstract 3.15.
19. Alcaide, F., Carratala, J., Linares, J., Gudiol, F. & Martin, R. (1995). In vitro activity of eight macrolide antibiotics and RP-59500 against viridans streptococci isolated from blood of neutropenic cancer patients. In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1995. Abstract E51. American Society for Microbiology, Washington, DC.
20. Doern, G. V., Ferraro, M. J., Brueggemann, A. B. & Ruoff, K. L. (1996). Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrobial Agents and Chemotherapy 40, 891-4.
21. Grimm, H. (1996). In vitro activity of quinupristin/dalfopristin (RP 59500) and 8 other antibiotics against Enterococcus faecium. In Program and Abstracts of the Third International Conference on the Macrolides, Azalides and Streptogramins, Lisbon 1996. Abstract 6.18.
22. Collins, L., Malanoski, G., Wennersten, C., Eliopoulos, M. G., Ferraro, M. J. & Moellering, R. C. (1992). In vitro activity of RP 59500, an injectable streptogramin antibiotic, against vancomycinresistant Gram-positive organisms. In Program and Abstracts of the Thirty-Second Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, 1992. Abstract 1311. American Society for Microbiology, Washington, DC.
23. Shonekan, D., Handwerger, S. & Mildvan, D. (1995). Comparative in vitro activities of RP 59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, CP-99,219, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria. In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1995. Abstract E124. American Society for Microbiology, Washington, DC.
24. Casewell, M. W., Seyed-Akhavani, M. & Wade, J. (1993). tovitro activity of RP 59500 against vancomycin-resistant Enterococcus faecium also resistant to >512 mg/L of gentamicin. In Program and Abstracts of the Thirty-Third Interscience Conference of Antimicrobial Agents and Chemotherapy, New Orleans, 1993. Abstract 313. American Society for Microbiology, Washington, DC.
25. Mahayni, R., Perri, M. B., Dembry, L. M. & Zervos, M. J. (1994), Comparative In-vltro and bactericidal activity of RP 59500 (quinupristin/dalfopristin), against multi-drug resistant E. faecium. In Program and Abstracts of the Thirty-Fourth Interscience Conference of Antimicrobial Agents and Chemotherapy, Orlando, 1994. Abstract 27. American Society for Microbiology, Washington, DC.
26. Pasculle, A. W., Linden, P. K., McDevitt, D. A., Wagener, J. L., McKnight, J. L. & Papafrangas, E. A. (1993). Susceptibility of vancomycin-resistant Enterococcus faecium (VREF) to alternative antimicrobial agents singly and in combination. In Program and Abstracts of the Thirty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1993. Abstract 1060. American Society for Microbiology, Washington, DC.
27. Lorian, V. & Fernandes, F. (1997). Synergic activity of vancomycin-quinupristin/dalfopristin combination against Enterococcus faecium. Journal of Antimicrobial Chemotherapy 39, Suppl. A, 63-6.
28. Steele Moore, L., Schneider, B. & Holloway, W. J. (1997). Minimal inhibitory concentrations and minimal bactericidal concentrations of quinupristin/dalfopristin against clinical isolates of Corynebacterium jeikeium and Listeria monocytogenes. Journal of Antimicrobial Chemotherapy 39, Suppl. A, 67-8.
29. Nord, C. E., Lindmark, A. & Persson, I. (1989). Susceptibility of anaerobic bacteria to the new streptogramin RP 59500 in vitro. European Journal of Clinical Microbiology and Infectious Diseases 8, 1064-7.
30. Appelbaum, P. C., Spangler, S. K. & Jacobs, M. R. (1991). Susceptibility of 139 penicillin-susceptible and resistant isolates of Streptococcus pneumoniae to RP 59500, erythrornycin, vancomycin, temafloxacin, ciprofloxacin and ofloxacin. In Program and Abstracts of the Thirty-First Interscience Conference of Antimicrobial Agents and Chemotherapy, Chicago, 1991. Abstract 893, American Society for Microbiology, Washington, DC.
31. Baquero, F., Bremmelgaard, A., Mittermayer, H., Privitera, G., Sedaillan, A., Werner, H. et al. (1993). Evaluation of the 'in vitro' activity of RP 59500 against anaerobic bacteria: a collaborative European study. In Program and Abstracts of the Thirty-Third Interscience Conference of Antimicrobial Agents and Chemotherapy, New Orleans, 1993. Abstract 467. American Society for Microbiology, Washington, DC.
32. Inoue, M., Okamoto, R., Okubo, T., Inoue, K. & Mitsuhashi, S. (1992). Comparative in-vitro activity of RP 59500 against clinical bacterial isolates. Journal of Antimicrobial Chemotherapy 30, Suppl. A, 45-51.
33. Soussy, C. J., Acar, J. F., Cluzel, R., Courvalin, P., Duval, J., Fleurette, J. et al. (1992). A collaborative study of the in-vitro sensitivity to RP 59500 of bacteria isolated in seven hospitals in France. Journal of Antimicrobial Chemotherapy 30, Suppl. A, 53-8.
34. Fantin, B., Leclercq, R., Merle, Y., Saint-Julien, L., Veyrat, C., Duval, J. et al. (1995). Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin/ dalfopristin) in experimental endocarditis due to Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 39, 400-5.
35. Caron, F., Gold, H. S., Wennersten, C. B., Moellering, R. C. & Eliopoulos, G. M. (1996). Role of growth phase and erythromycin susceptibility on the bactericidal effect of RP 59500 (quinupristin/ dalfopristin) against vancomycin-resistant Enterococcus faecium. In Program and Abstracts of the Third International Conference on Macrolides, Azalides and Streptogramins, Lisbon, 1996.
36. Williams, J. D., Maskell, J. P., Whiley, A. C. & Sefton, A. M. (1997). Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp. Journal of Antimicrobial Chemotherapy 39, Suppl. A, 41-6.
37. Chin, N. X. & Neu, H. C. (1992). Post-antibiotic effect of the new streptogramin RP 59500. European Journal of Clinical Microbiology and Infectious Diseases 11, 642-5.
38. Boswell, F. J., Andrews, J. M. & Wise, R. (1994), The postantibiotic effect of RP 59500 on Staphylococcus aureus including strains with a raised MBC. Journal of Antimicrobial Chemotherapy 33, 1219-22.
39. Nougayrede, A., Berthaud, N. & Bouanchaud, D. H. (1992). Post-antibiotic effects of RP 59500 with Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 30, Suppl. A, 101-6.
40. Craig, W. & Ebert, S. (1993). Pharmacodynamic activities of RP 59500 in an animal infection model. In Program and Abstracts of the Thirty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1993. Abstract 470. American Society for Microbiology, Washington, DC.
41. Brumfitt, W., Hamilton-Miller, J. M. T. & Shah, S. (1992). Invitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against Gram-positive bacteria. Journal of Antimicrobial Chemotherapy 30, Suppl. A, 29-37.
42. Desnottes, J. F. & Diallo, N. (1992). Cellular uptake and intracellular bactericidal activity of RP 59500 in murine macrophages. Journal of Antimicrobial Chemotherapy 30, Suppl. A, 107-15.
43. Tenover, F. C. & Baker, C. N. (1997). Development of provisional disk diffusion breakpoints for testing quinupristin/ dalfopristin. Journal of Antimicrobial Chemotherapy 39, Suppl. A, 81-5.
44. Aldridge, K. E., Schiro, D. D. & Varner, L. M. (1992). In vitro antistaphylococcal activity of RP 59500, a new streptogramin, by two methods. Antimicrobial Agents and Chemotherapy 36, 854-5.
45. Hamilton-Miller, J. M. T. & Shah, S. (1995). Killing of Staphylococcus epidermidis in biofilm by RP 59500 (quinupristin/dalfopristin) and other antibiotics. In Program and Abstracts of the Thirty-Fifth interscience Conference of Antimicrobial Agents and Chemotherapy, San Francisco, 1995. Abstract A104. American Society for Microbiology, Washington, DC.
46. Tarasi, A. & Tomasz, A. (1995). Activity of RP 59500 against multidrug resistant clones of Streptococcus pneumoniae. in Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1995. Abstract E116. American Society for Microbiology, Washington, DC.
47. Scriver, S. R., Tyrrell, G., Willey, B. M., Kreiswirth, B. N. & Low, D. E. (1993). In vitro assessment of RP 59500 (RP) against vancomycin-resistant enterococci. In Program and Abstracts of the Thirty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1993. Abstract 1057. American Society for Microbiology, Washington, DC.
48. Dabernat, H., Seguy, M. & Delmas, C. (1993). In vitro activity of RP 59500, a semi-synthetic streptogramin, against Haemophiius influenzae. In Program and Abstracts of the Thirty-Third Interscience Conference of Antimicrobial Agents and Chemotherapy, New Orleans, 1993. Abstract 226. American Society for Microbiology, Washington, DC.
49. Andrews, J. M., Boswell, F. & Wise, R. (1993). In vitro activity of RP 59500 against staphylococci and respiratory pathogens. In Program and Abstracts of the Thirty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1993, Abstract 1044. American Society for Microbiology, Washington, DC.
50. Dubois, J. & Joly, J. R. (1992). In-vitro activity of RP 59500, a new synergic antibacterial agent, against Legionella spp. Journal of Antimicrobial Chemotherapy 30, Suppl. A, 77-81.
51. Renaudin, H., Boussens, B. & Bebear, C. (1991). In-vitro activity of RP 59500 against Mycoplasma. In Program and Abstracts of the Thirty-First Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 1991. Abstract 897. American Society for Microbiology, Washington, DC.